Whistleblower Reports Raise Corruption Concerns over Pharmaceutical Giants’ Russian Cancer Drug Contracts

Confidential whistleblower reports have raised allegations that four major pharmaceutical companies paid substantial bonuses to Russian distributors involved in government medicine procurement, potentially creating financial incentives for corruption and contributing to higher prices for cancer treatments.

The reports concern Merck, Eli Lilly, Novartis and AstraZeneca, which allegedly paid bonuses and rebates ranging from 15% to 35% to Russian distributors and sub-distributors between 2020 and 2023. According to the disclosures, these intermediaries may have used the additional margins to finance improper payments to government healthcare officials and hospital administrators in exchange for public contracts and increased prescriptions of expensive medicines.

The allegations form part of a collection of hundreds of pages of documents submitted to the US Securities and Exchange Commission (SEC). The material reportedly includes internal company emails, procurement records and letters addressed to the pharmaceutical companies’ audit committees. The whistleblower, described as a long-time pharmaceutical industry employee, also indicated that the information would be provided to the US Department of Justice.

The companies named in the reports are associated with several widely used cancer treatments, including Merck’s Keytruda, Eli Lilly’s Cyramza, Novartis’ Kisqali and AstraZeneca’s Tagrisso. The disclosures allege that distributors received unusually large commercial incentives despite having been linked to non-competitive bidding practices, alleged bid rigging or other competition-related investigations.

An investigation of Russian public procurement records identified significant patterns of single-participant bidding. In the case of AstraZeneca’s Tagrisso, approximately 95% of government bids between 2020 and 2023 reportedly involved only one participant. The whistleblower alleged that the lack of competition allowed the medicine to be sold at prices slightly above its official list price, which was approximately US$3,000–US$3,500 for a pack of 30 tablets during the period examined.

Similar concerns were raised in relation to Eli Lilly’s Cyramza. Nine contracts awarded by the Moscow City Department of Health in 2021 were valued at more than US$5 million and were reportedly won by Pharmstandard, frequently as the sole bidder. According to the whistleblower disclosures, Lilly provided the distributor with a 29% volume-based bonus for achieving annual sales targets and a further 5% incentive for timely payment.

The investigation also examined contracts involving AstraZeneca’s Koselugo, a treatment for children with a rare type of tumour. Between 2022 and 2024, Pharmimex reportedly secured approximately US$114.3 million in government contracts out of a total market value of nearly US$129 million, with most awards following single-participant bidding procedures. The disclosures raised concerns that sub-distributors and companies allegedly operating as shell entities were used to create additional layers between pharmaceutical manufacturers and government procurement processes.

Merck’s relationship with Russian distributor R-Pharm, founded by businessman Alexey Repik, was another major focus. R-Pharm became a significant supplier of Keytruda to Russian public hospitals, winning approximately 2,400 out of nearly 5,000 procurement bids between 2020 and 2022. The contracts won by the company were worth around US$360 million, compared with a total market value of approximately US$870 million. Procurement records indicated that 96% of Keytruda bids during the period involved only one participating company.

R-Pharm has previously faced scrutiny from Russian competition authorities over alleged anti-competitive conduct and coordination of bids with other distributors. The company’s representatives have denied involvement in improper payments or arrangements intended to secure non-competitive government contracts. R-Pharm has also argued that its role in supplying Keytruda was connected to its licence to act as Merck’s local production partner, noting that the medicine was protected by a patent and had no competing product in Russia at the time.

The allegations also concern the wider pharmaceutical distribution system. Russian procurement investigations have identified cases in which distributors allegedly received preferential information about planned purchases, tender requirements and delivery conditions. In one earlier case, the country’s anti-monopoly agency found that a state-funded oncology centre in the Penza region had provided Pharmimex with information that created preferential treatment in the procurement process. The proceedings against Pharmimex itself were discontinued, while the medical institution was found to have violated competition rules.

The scale of the reported commercial incentives has attracted particular attention. A confidential industry survey conducted by Russian audit firm Kept found that the average bonus paid to distributors supplying government entities in Russia in 2022 was approximately 30%. This was substantially higher than the incentives reportedly paid to retail distributors. Kept, however, cautioned that the two markets were not directly comparable because retail distribution involves additional intermediaries and operating costs. It also maintained that bonus arrangements are commercial mechanisms and do not determine the effectiveness of public procurement.

The allegations carry potential implications under the US Foreign Corrupt Practices Act (FCPA), which prohibits companies from bribing foreign public officials to obtain or retain business and imposes accounting and internal-control obligations on publicly traded companies. Using an intermediary does not automatically protect a manufacturer from liability where it knows, or deliberately ignores warning signs, that a distributor may be using its margins to finance improper payments.

The disclosures therefore raise questions about the adequacy of third-party due diligence and the effectiveness of internal compliance controls at the pharmaceutical companies involved. Relevant risk indicators include unusually high distributor bonuses, non-competitive tender outcomes, opaque ownership structures, the use of sub-distributors and previous regulatory investigations involving commercial partners. Companies operating through distributors in high-risk markets are expected to assess these factors and maintain appropriate oversight of their business relationships.

The companies have responded differently to the allegations. Novartis stated that it had conducted a thorough investigation into the specific FCPA concerns but did not disclose its findings. AstraZeneca declined to comment, while Merck and Eli Lilly did not respond to requests for comment. R-Pharm denied any involvement by the company, its officers or affiliates in improper payments to public officials and maintained that its activities comply with applicable laws and ethical standards. The whistleblower reports do not provide direct evidence of payments from the intermediaries to government officials, and the allegations should not be treated as established findings of criminal wrongdoing.

The case highlights the risks that can arise when pharmaceutical manufacturers rely on third-party distributors to access government-funded healthcare markets. Where substantial financial incentives are combined with limited competition, politically connected intermediaries and repeated procurement irregularities, companies may face significant corruption, regulatory and reputational exposure. It also illustrates why distributor due diligence, transparent incentive structures and ongoing monitoring are important elements of an effective anti-bribery compliance programme, particularly where public procurement involves high-value medicines and vulnerable patient populations.

By fLEXI tEAM